Every 8-K that Royalty Pharma plc (RPRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RPRX filings page.
Royalty Pharma plc reported second quarter 2026 results and raised full-year 2026 guidance for Portfolio Receipts. Portfolio Receipts were $773 million, up 6%, and Royalty Receipts were $768 million, up 14%, driven by Tremfya, Voranigo, Imdelltra and Evrysdi. Net cash provided by operating activities doubled to $728 million. Adjusted EBITDA and Portfolio Cash Flow each reached $736 million, reflecting payments for operating and professional costs at 4.8% of Portfolio Receipts.
The company now expects 2026 Portfolio Receipts of $3,400 million to $3,500 million, versus $3,325 million to $3,450 million previously, implying expected Royalty Receipts growth of 7% to 10%. Cash and cash equivalents were $812 million and total debt principal was $9.2 billion as of June 30, 2026; a $380 million term loan was repaid in July. Capital Deployment was $349 million in the quarter, including royalty funding for daraxonrasib and R&D funding for JNJ‑4804 and litifilimab. Net income attributable to Royalty Pharma plc was $18 million compared with $32 million a year earlier.
Royalty Pharma plc reported the voting results from its 2026 Annual General Meeting of Shareholders. Shareholders representing 508,180,103 Class A and Class B shares, or 88.08% of eligible voting power, were present or represented, providing a strong quorum.
All nine director nominees were elected to serve until the 2027 annual meeting. Shareholders approved, on a non-binding advisory basis, compensation for named executive officers and the U.K. directors’ remuneration report. They also ratified Ernst & Young LLP as independent registered public accounting firm and re-appointed Ernst & Young as U.K. statutory auditor.
Shareholders authorized the board to determine the U.K. auditor’s remuneration, approve terms for potential repurchases of Class A ordinary shares, and grant the board authority to allot shares, including authority to allot shares without rights of pre-emption.
Royalty Pharma plc entered into a new $1.8 billion unsecured revolving credit facility with Bank of America and a syndicate of lenders. This facility replaces the company’s prior revolving credit agreement, and all obligations and commitments under the old facility were fully repaid and terminated at effectiveness.
The new Revolving Credit Facility bears interest at either a base rate tied to prime, federal funds plus 0.5%, or Term SOFR plus 1%, or at SOFR/alternative currency rates plus an applicable margin, with a commitment fee on unused amounts. It matures on May 22, 2031 and includes financial covenants requiring a consolidated leverage ratio at or below 4.00 to 1.00, a portfolio cash flow ratio at or below 5.00 to 1.00, and a coverage ratio at or above 2.50 to 1.00, with slightly higher leverage and cash flow limits following qualifying material acquisitions.
Royalty Pharma plc reported strong first-quarter 2026 results, with double-digit growth and higher full-year guidance. Portfolio Receipts rose 10% to $925 million, while Royalty Receipts grew 13% to $887 million, driven mainly by Tremfya, Voranigo and Evrysdi. Net cash provided by operating activities increased 20% to $718 million.
Adjusted EBITDA climbed 21% to $889 million and Portfolio Cash Flow rose 18% to $722 million, highlighting robust cash generation. The company raised 2026 Portfolio Receipts guidance to $3,325 million–$3,450 million, implying expected Royalty Receipts growth of 4%–8%. Royalty Pharma also executed $528 million of capital deployment, including three royalty acquisitions with up to $1.25 billion in announced value, paid a quarterly dividend of $0.235 per share and repurchased about 1.1 million shares.
Royalty Pharma plc highlights positive Phase 3 results from partner Revolution Medicines’ RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. The study met all primary and key secondary endpoints, including progression-free and overall survival, and Revolution Medicines plans to submit the data to global regulators, including a future U.S. FDA New Drug Application.
These results activate the second $250 million tranche under a previously announced $2 billion funding deal between the companies, bringing Royalty Pharma’s funding to $500 million so far. Royalty Pharma is now entitled to tiered royalties of 4.55% on daraxonrasib (and certain zoldonrasib sales), with potential step-ups to as high as 7.80% on lower sales tiers if Revolution Medicines draws the remaining synthetic royalty funding, alongside access to a senior secured term loan facility of up to $750 million linked to FDA approval and future sales milestones.
Royalty Pharma plc reported strong growth for Q4 and full year 2025 and issued 2026 guidance. Portfolio Receipts rose 18% in Q4 2025 to $874 million and 16% for 2025 to $3,254 million, while Royalty Receipts grew 13% to $3,127 million, led by Voranigo, Trelegy, Tremfya and the cystic fibrosis franchise.
Adjusted EBITDA increased 16% to $2,966 million and Portfolio Cash Flow rose 11% to $2,724 million in 2025, though net cash from operating activities declined to $2,490 million from $2,769 million. The company deployed $2.6 billion on royalty transactions and repurchased 37 million shares for $1.2 billion, alongside $512 million of dividends, supported by $619 million of cash and $9.2 billion of debt at year-end.
For 2026, Royalty Pharma expects Portfolio Receipts of $3,275 million to $3,425 million, implying Royalty Receipts growth of 3% to 8%, with lower operating and professional costs as a percentage of Portfolio Receipts following the internalization of its external manager and interest paid projected at $350 million to $360 million.
Royalty Pharma plc furnished an Item 2.02 Form 8-K announcing its financial results press release for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and the Cover Page Inline XBRL is listed as Exhibit 104.
The information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly stated.
Royalty Pharma plc completed a major debt financing, closing an offering of $600 million 4.450% Senior Notes due 2031, $900 million 5.200% Senior Notes due 2035, and $500 million 5.950% Senior Notes due 2055.
The notes are senior unsecured obligations and are guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. Interest on all three series will be paid semi-annually on March 25 and September 25, beginning March 25, 2026, with final maturities matching each series’ stated due date.
The indenture includes customary covenants and requires Royalty Pharma to offer to repurchase the notes upon certain change of control events. The company also entered into an underwriting agreement with a syndicate of major investment banks that sets the terms and conditions for the sale of these notes.
Royalty Pharma plc reported that Henry Fernandez has stepped down as a member of the Board and as the Board's Lead Independent Director, effective August 13, 2025. The filing states his decision did not result from any disagreement with the company and notes his five years of service and the Board's gratitude for his contributions.
The company disclosed that it issued a press release announcing the departure, which is filed as Exhibit 99.1 and is incorporated by reference. No successor or additional governance changes are described in the filing.